The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710)

Results of two Phase I studies

Clayton D. Harro, Robert F. Betts, Jonathan S. Hartzel, Matthew T. Onorato, Joy Lipka, Steven S. Smugar, Nicholas A. Kartsonis

Research output: Contribution to journalArticle

Abstract

Merck V710 is a novel vaccine that contains the highly conserved Staphylococcus aureus iron surface determinant B (IsdB) protein. V710 has induced positive immune responses in healthy subjects. The purpose of the two studies described herein was to evaluate the immunogenicity and safety of two different formulations of V710. Both studies were randomized, controlled, double-blind, parallel-group trials. Study 1 compared liquid, aluminum-adjuvanted V710 (30 μg) with liquid, non-adjuvanted V710 (30 μg) in a 1:1 ratio in 64 healthy adults (18-70 years). Study 2 compared non-adjuvanted lyophilized V710 (60 μg) with saline placebo in a 4:1 ratio in 51 healthy adults (18-80 years). Blood was collected at screening and up to Day 360 postvaccination in Study 1, and at screening and up to Day 84 postvaccination in Study 2. Sera were analyzed for IsdB-specific antibodies using a total IgG assay. The primary endpoints in Study 1 were the proportion of patients with a positive immune response (≥2-fold rise in IsdB-specific IgG antibody level) the geometric mean concentration (GMC), and the geometric mean-fold rise (GMFR), all from baseline at Day 14. The primary endpoint in Study 2 was the GMFR in IsdB-specific IgG antibody concentration from baseline at Day 14. In Study 1, 84.4% responded in the adjuvanted V710 group, and 71.9% in the non-adjuvanted V710 group. The GMC was 115.4 μg/mL in the adjuvanted group and 99.1 μg/mL in the nonadjuvanted group. The GMFR in antibody concentration in the group receiving aluminum-adjuvanted V710 was 4.5 and the GMFR in the group receiving non-adjuvanted V710 was 4.0. In Study 2, the GMFR in antibody concentration in the V710 group was 5.3, and 80.5% had a positive immune response. None responded in the placebo group. Positive immune response was seen in the active treatment groups over the full duration of each study. There were no serious adverse experiences (AE) in either study, and no patients discontinued due to an AE. There were no clinically meaningful differences in AEs between groups in either study. In conclusion, V710, both with and without aluminum adjuvant, and in both liquid and lyophilized formulations, was immunogenic within 14 days of vaccination. All treatments showed similar safety profiles.

Original languageEnglish (US)
Pages (from-to)1729-1736
Number of pages8
JournalVaccine
Volume30
Issue number9
DOIs
StatePublished - Feb 21 2012

Fingerprint

Staphylococcus aureus
immune response
vaccines
Safety
antibodies
Aluminum
Antibodies
iron
aluminum
Iron
Immunoglobulin G
endpoints
placebos
liquids
Placebos
screening
blood serum
adjuvants
Healthy Volunteers
Vaccination

Keywords

  • Adjuvant
  • Immunogenicity
  • Iron surface determinant (IsdB)
  • Phase I
  • Staphylococcus aureus
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Harro, C. D., Betts, R. F., Hartzel, J. S., Onorato, M. T., Lipka, J., Smugar, S. S., & Kartsonis, N. A. (2012). The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): Results of two Phase I studies. Vaccine, 30(9), 1729-1736. https://doi.org/10.1016/j.vaccine.2011.12.045

The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710) : Results of two Phase I studies. / Harro, Clayton D.; Betts, Robert F.; Hartzel, Jonathan S.; Onorato, Matthew T.; Lipka, Joy; Smugar, Steven S.; Kartsonis, Nicholas A.

In: Vaccine, Vol. 30, No. 9, 21.02.2012, p. 1729-1736.

Research output: Contribution to journalArticle

Harro, CD, Betts, RF, Hartzel, JS, Onorato, MT, Lipka, J, Smugar, SS & Kartsonis, NA 2012, 'The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): Results of two Phase I studies', Vaccine, vol. 30, no. 9, pp. 1729-1736. https://doi.org/10.1016/j.vaccine.2011.12.045
Harro, Clayton D. ; Betts, Robert F. ; Hartzel, Jonathan S. ; Onorato, Matthew T. ; Lipka, Joy ; Smugar, Steven S. ; Kartsonis, Nicholas A. / The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710) : Results of two Phase I studies. In: Vaccine. 2012 ; Vol. 30, No. 9. pp. 1729-1736.
@article{1e27fad233f54469b342a91046920b2d,
title = "The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): Results of two Phase I studies",
abstract = "Merck V710 is a novel vaccine that contains the highly conserved Staphylococcus aureus iron surface determinant B (IsdB) protein. V710 has induced positive immune responses in healthy subjects. The purpose of the two studies described herein was to evaluate the immunogenicity and safety of two different formulations of V710. Both studies were randomized, controlled, double-blind, parallel-group trials. Study 1 compared liquid, aluminum-adjuvanted V710 (30 μg) with liquid, non-adjuvanted V710 (30 μg) in a 1:1 ratio in 64 healthy adults (18-70 years). Study 2 compared non-adjuvanted lyophilized V710 (60 μg) with saline placebo in a 4:1 ratio in 51 healthy adults (18-80 years). Blood was collected at screening and up to Day 360 postvaccination in Study 1, and at screening and up to Day 84 postvaccination in Study 2. Sera were analyzed for IsdB-specific antibodies using a total IgG assay. The primary endpoints in Study 1 were the proportion of patients with a positive immune response (≥2-fold rise in IsdB-specific IgG antibody level) the geometric mean concentration (GMC), and the geometric mean-fold rise (GMFR), all from baseline at Day 14. The primary endpoint in Study 2 was the GMFR in IsdB-specific IgG antibody concentration from baseline at Day 14. In Study 1, 84.4{\%} responded in the adjuvanted V710 group, and 71.9{\%} in the non-adjuvanted V710 group. The GMC was 115.4 μg/mL in the adjuvanted group and 99.1 μg/mL in the nonadjuvanted group. The GMFR in antibody concentration in the group receiving aluminum-adjuvanted V710 was 4.5 and the GMFR in the group receiving non-adjuvanted V710 was 4.0. In Study 2, the GMFR in antibody concentration in the V710 group was 5.3, and 80.5{\%} had a positive immune response. None responded in the placebo group. Positive immune response was seen in the active treatment groups over the full duration of each study. There were no serious adverse experiences (AE) in either study, and no patients discontinued due to an AE. There were no clinically meaningful differences in AEs between groups in either study. In conclusion, V710, both with and without aluminum adjuvant, and in both liquid and lyophilized formulations, was immunogenic within 14 days of vaccination. All treatments showed similar safety profiles.",
keywords = "Adjuvant, Immunogenicity, Iron surface determinant (IsdB), Phase I, Staphylococcus aureus, Vaccine",
author = "Harro, {Clayton D.} and Betts, {Robert F.} and Hartzel, {Jonathan S.} and Onorato, {Matthew T.} and Joy Lipka and Smugar, {Steven S.} and Kartsonis, {Nicholas A.}",
year = "2012",
month = "2",
day = "21",
doi = "10.1016/j.vaccine.2011.12.045",
language = "English (US)",
volume = "30",
pages = "1729--1736",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "9",

}

TY - JOUR

T1 - The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710)

T2 - Results of two Phase I studies

AU - Harro, Clayton D.

AU - Betts, Robert F.

AU - Hartzel, Jonathan S.

AU - Onorato, Matthew T.

AU - Lipka, Joy

AU - Smugar, Steven S.

AU - Kartsonis, Nicholas A.

PY - 2012/2/21

Y1 - 2012/2/21

N2 - Merck V710 is a novel vaccine that contains the highly conserved Staphylococcus aureus iron surface determinant B (IsdB) protein. V710 has induced positive immune responses in healthy subjects. The purpose of the two studies described herein was to evaluate the immunogenicity and safety of two different formulations of V710. Both studies were randomized, controlled, double-blind, parallel-group trials. Study 1 compared liquid, aluminum-adjuvanted V710 (30 μg) with liquid, non-adjuvanted V710 (30 μg) in a 1:1 ratio in 64 healthy adults (18-70 years). Study 2 compared non-adjuvanted lyophilized V710 (60 μg) with saline placebo in a 4:1 ratio in 51 healthy adults (18-80 years). Blood was collected at screening and up to Day 360 postvaccination in Study 1, and at screening and up to Day 84 postvaccination in Study 2. Sera were analyzed for IsdB-specific antibodies using a total IgG assay. The primary endpoints in Study 1 were the proportion of patients with a positive immune response (≥2-fold rise in IsdB-specific IgG antibody level) the geometric mean concentration (GMC), and the geometric mean-fold rise (GMFR), all from baseline at Day 14. The primary endpoint in Study 2 was the GMFR in IsdB-specific IgG antibody concentration from baseline at Day 14. In Study 1, 84.4% responded in the adjuvanted V710 group, and 71.9% in the non-adjuvanted V710 group. The GMC was 115.4 μg/mL in the adjuvanted group and 99.1 μg/mL in the nonadjuvanted group. The GMFR in antibody concentration in the group receiving aluminum-adjuvanted V710 was 4.5 and the GMFR in the group receiving non-adjuvanted V710 was 4.0. In Study 2, the GMFR in antibody concentration in the V710 group was 5.3, and 80.5% had a positive immune response. None responded in the placebo group. Positive immune response was seen in the active treatment groups over the full duration of each study. There were no serious adverse experiences (AE) in either study, and no patients discontinued due to an AE. There were no clinically meaningful differences in AEs between groups in either study. In conclusion, V710, both with and without aluminum adjuvant, and in both liquid and lyophilized formulations, was immunogenic within 14 days of vaccination. All treatments showed similar safety profiles.

AB - Merck V710 is a novel vaccine that contains the highly conserved Staphylococcus aureus iron surface determinant B (IsdB) protein. V710 has induced positive immune responses in healthy subjects. The purpose of the two studies described herein was to evaluate the immunogenicity and safety of two different formulations of V710. Both studies were randomized, controlled, double-blind, parallel-group trials. Study 1 compared liquid, aluminum-adjuvanted V710 (30 μg) with liquid, non-adjuvanted V710 (30 μg) in a 1:1 ratio in 64 healthy adults (18-70 years). Study 2 compared non-adjuvanted lyophilized V710 (60 μg) with saline placebo in a 4:1 ratio in 51 healthy adults (18-80 years). Blood was collected at screening and up to Day 360 postvaccination in Study 1, and at screening and up to Day 84 postvaccination in Study 2. Sera were analyzed for IsdB-specific antibodies using a total IgG assay. The primary endpoints in Study 1 were the proportion of patients with a positive immune response (≥2-fold rise in IsdB-specific IgG antibody level) the geometric mean concentration (GMC), and the geometric mean-fold rise (GMFR), all from baseline at Day 14. The primary endpoint in Study 2 was the GMFR in IsdB-specific IgG antibody concentration from baseline at Day 14. In Study 1, 84.4% responded in the adjuvanted V710 group, and 71.9% in the non-adjuvanted V710 group. The GMC was 115.4 μg/mL in the adjuvanted group and 99.1 μg/mL in the nonadjuvanted group. The GMFR in antibody concentration in the group receiving aluminum-adjuvanted V710 was 4.5 and the GMFR in the group receiving non-adjuvanted V710 was 4.0. In Study 2, the GMFR in antibody concentration in the V710 group was 5.3, and 80.5% had a positive immune response. None responded in the placebo group. Positive immune response was seen in the active treatment groups over the full duration of each study. There were no serious adverse experiences (AE) in either study, and no patients discontinued due to an AE. There were no clinically meaningful differences in AEs between groups in either study. In conclusion, V710, both with and without aluminum adjuvant, and in both liquid and lyophilized formulations, was immunogenic within 14 days of vaccination. All treatments showed similar safety profiles.

KW - Adjuvant

KW - Immunogenicity

KW - Iron surface determinant (IsdB)

KW - Phase I

KW - Staphylococcus aureus

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84856803210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856803210&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.12.045

DO - 10.1016/j.vaccine.2011.12.045

M3 - Article

VL - 30

SP - 1729

EP - 1736

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 9

ER -